Adenosine A2A Receptor Antagonists in Parkinson’s Disease: Progress in Clinical Trials from the Newly Approved Istradefylline to Drugs in Early Development and Those Already Discontinued

Istradefylline: First Global Approval

(2013) Rosselle Dungo et al.   DRUGS

Preladenant, a selective adenosine A2A receptor antagonist, is not associated with QT/QTc prolongation

(2013) Z. Wang et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Synthesis and Biological Evaluation of Metabolites of 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535), A Potent Antagonist of the A2A Adenosine Receptor for the Treatment of Parkinson’s Disease

(2013) Giovanni Piersanti et al.   JOURNAL OF MEDICINAL CHEMISTRY

Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease

(2013) Stewart A. Factor et al.   MOVEMENT DISORDERS

Adenosine A2Areceptor antagonist istradefylline reduces daily OFF time in Parkinson's disease

(2013) Yoshikuni Mizuno et al.   MOVEMENT DISORDERS

Adenosine A2A Antagonists in Parkinson’s Disease: What’s Next?

(2012) Patrick Hickey et al.   Current Neurology and Neuroscience Reports

Safety, tolerability and pharmacokinetics after single and multiple doses of preladenant (SCH420814) administered in healthy subjects

(2012) D. L. Cutler et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Istradefylline, an adenosine A2A receptor antagonist, for patients with Parkinson's Disease: A meta-analysis

(2012) Wanqiang Chen et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Adenosine A2A Receptor Antagonists and Parkinson’s Disease

(2011) Brian C. Shook et al.   ACS Chemical Neuroscience

Adenosine A2A receptor in the monkey basal ganglia: Ultrastructural localization and colocalization with the metabotropic glutamate receptor 5 in the striatum

(2011) James W. Bogenpohl et al.   JOURNAL OF COMPARATIVE NEUROLOGY

Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial

(2011) Robert A Hauser et al.   LANCET NEUROLOGY

Milestones in Parkinson's disease therapeutics

(2011) Olivier Rascol et al.   MOVEMENT DISORDERS

Istradefylline for Parkinson's disease patients experiencing motor fluctuations: Results of the KW-6002-US-018 study

(2011) Emmanuelle Pourcher et al.   PARKINSONISM & RELATED DISORDERS

Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease

(2011) Marie Therese Armentero et al.   PHARMACOLOGY & THERAPEUTICS

An Open-Label, Positron Emission Tomography Study to Assess Adenosine A2A Brain Receptor Occupancy of Vipadenant (BIIB014) at Steady-State Levels in Healthy Male Volunteers

(2010) David J. Brooks et al.   CLINICAL NEUROPHARMACOLOGY

Preladenant, a selective A2A receptor antagonist, is active in primate models of movement disorders

(2010) Robert A. Hodgson et al.   EXPERIMENTAL NEUROLOGY

Population Pharmacokinetic Analysis of Istradefylline in Healthy Subjects and in Patients With Parkinson's Disease

(2010) William Knebel et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Quantification of Indirect Pathway Inhibition by the Adenosine A2a Antagonist SYN115 in Parkinson Disease

(2010) K. J. Black et al.   JOURNAL OF NEUROSCIENCE

Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: A randomized, controlled study

(2010) Yoshikuni Mizuno et al.   MOVEMENT DISORDERS

A long-term study of istradefylline in subjects with fluctuating Parkinson's disease

(2010) Stewart Factor et al.   PARKINSONISM & RELATED DISORDERS

Novel investigational adenosine A2Areceptor antagonists for Parkinson's disease

(2009) Annalisa Pinna   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Characterization of the Potent and Highly Selective A2A Receptor Antagonists Preladenant and SCH 412348 [7-[2-[4-2,4-Difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in Rodent Models of Movement Disorders and Depression

(2009) R. A. Hodgson et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Proposed neuroimaging criteria for the diagnosis of multiple system atrophy

(2009) David J. Brooks et al.   MOVEMENT DISORDERS

Istradefylline as monotherapy for Parkinson disease: Results of the 6002-US-051 trial

(2009) H.H. Fernandez et al.   PARKINSONISM & RELATED DISORDERS

Adenosine A2Areceptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005)

(2008) Peter A. LeWitt et al.   ANNALS OF NEUROLOGY

Evidence-Based Efficacy Comparison of Tolcapone and Entacapone as Adjunctive Therapy in Parkinson's Disease

(2008) Andrew J. Lees   CNS Neuroscience & Therapeutics

Adenosine A2A Receptor Antagonists and Parkinsons Disease: State of the Art and Future Directions

(2008) N. Simola et al.   CURRENT PHARMACEUTICAL DESIGN

Tremorolytic effects of adenosine A2A antagonists: implications for parkinsonism

(2008) John et al.   Frontiers in Bioscience-Landmark

Antagonists of the Human A2AAdenosine Receptor. 4. Design, Synthesis, and Preclinical Evaluation of 7-Aryltriazolo[4,5-d]pyrimidines

(2008) Roger J. Gillespie et al.   JOURNAL OF MEDICINAL CHEMISTRY

Epidemiology of Parkinson’s disease

(2008) Guido Alves et al.   JOURNAL OF NEUROLOGY

Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations

(2008) Robert A. Hauser et al.   MOVEMENT DISORDERS

A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease

(2008) M. Stacy et al.   NEUROLOGY

Positron emission tomography analysis of [11C]KW‐6002 binding to human and rat adenosine A2Areceptors in the brain

(2008) D.J. Brooks et al.   SYNAPSE

Adenosine receptor antagonists for cognitive dysfunction: a review of animal studies

(2007) Reinaldo Naoto Takahashi   Frontiers in Bioscience-Landmark